Alignment of European Regulatory and Health Technology Assessments: A Review of Licensed Products for Alzheimer's Disease.
Ontology highlight
ABSTRACT: Aims: To facilitate regulatory learning, we evaluated similarities and differences in evidence requirements between regulatory and health technology assessment (HTA) bodies of Alzheimer's disease (AD) approved products. Methods: The European marketing authorisation application dossiers and European public assessment reports (EPARs) of the licensed AD drugs were screened to identify the phase III randomised controlled trials (RCTs) and outcomes used. We also screened the assessment reports of the National Institute of Health and Care Excellence (NICE, England) and the National Health Care Institute (ZiN, the Netherlands) to identify the studies and outcomes used in HTA assessments. Results: The application dossiers of donepezil, galantamine, rivastigmine, and memantine
SUBMITTER: Dekker MJHJ
PROVIDER: S-EPMC6515927 | biostudies-literature | 2019
REPOSITORIES: biostudies-literature
ACCESS DATA